ReviewInflammatory bowel diseases2011
Pharmacological intervention studies using mouse models of the inflammatory bowel diseases: translating preclinical data into new drug therapies.
Review in Inflammatory bowel diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Microbiota as a modulator of drug response: targeting microbial-drug crosstalk in cancer therapy.Gut microbes · 2026Review
- A Novel Synbiotic Protects Against DSS-Induced Colitis in Mice via Anti-inflammatory and Microbiota-Balancing Properties.Probiotics and antimicrobial proteins · 2025Article
- In Vitro and In Vivo Characterization of 40 kDa PEGylated Adrenomedullin in a DSS-Induced Colitis Model.International journal of molecular sciences · 2025Article
- Elevated risk of adverse effects from foodborne contaminants and drugs in inflammatory bowel disease: a review.Archives of toxicology · 2024Review
- Article
- Macrophage polarization toward M1 phenotype in T cell transfer colitis model.BMC gastroenterology · 2023Article
- Protective Effect of Saffron in Mouse Colitis Models Through Immune Modulation.Digestive diseases and sciences · 2022Article
- Leaky gut model of the human intestinal mucosa for testing siRNA-based nanomedicine targeting JAK1.Journal of controlled release : official journal of the Controlled Release Society · 2022Article
- Selection of a novel strain of Christensenella minuta as a future biotherapy for Crohn's disease.Scientific reports · 2022Article
- Genomic, microbial and environmental standardization in animal experimentation limiting immunological discovery.BMC immunology · 2020Review
- Total CD3 T Cells Are Necessary and Sufficient to Induce Colitis in Immunodeficient Mice With Dendritic Cell-Specific Deletion of TGFbR2: A Novel IBD Model to Study CD4 and CD8 T-Cell Interaction.Inflammatory bowel diseases · 2020Article
- Exploratory clinical characterization of experimentally-induced ulcerative colitis nonhuman primates.Heliyon · 2020Article
- Antioxidant Activity of Yogurt Fermented at Low Temperature and Its Anti-inflammatory Effect on DSS-induced Colitis in Mice.Food science of animal resources · 2019Article
- Reproducing the human mucosal environment ex vivo: inflammatory bowel disease as a paradigm.Current opinion in gastroenterology · 2018Review
- Sinomenine alleviates dextran sulfate sodium‑induced colitis via the Nrf2/NQO‑1 signaling pathway.Molecular medicine reports · 2018Article
- Humanizing the mouse immune system to study splanchnic organ inflammation.The Journal of physiology · 2018Review
- Differential Susceptibility to T Cell-Induced Colitis in Mice: Role of the Intestinal Microbiota.Inflammatory bowel diseases · 2018Article
- Possible Involvement of Liver Resident Macrophages (Kupffer Cells) in the Pathogenesis of Both Intrahepatic and Extrahepatic Inflammation.Canadian journal of gastroenterology & hepatology · 2017Article
- Fructooligosaccharides exert intestinal anti-inflammatory activity in the CD4+ CD62L+ T cell transfer model of colitis in C57BL/6J mice.European journal of nutrition · 2016Article
- Protective and pro-inflammatory roles of intestinal bacteria.Pathophysiology : the official journal of the International Society for Pathophysiology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Most therapeutic agents used in clinical practice today were originally developed and tested in animal models so that drug toxicity and safety, dose-responses, and efficacy could be determined. Retrospective analyses of preclinical intervention studies using animal models of different diseases demonstrate that only a small percentage of the interventions reporting promising effects translate to clinical efficacy. The failure to translate therapeutic efficacy from bench to bedside may be due, in part, to shortcomings in the design of the clinical studies; however, it is becoming clear that much of the problem resides within the preclinical studies. One potential strategy for improving our ability to identify new therapeutics that may have a reasonable chance of success in clinical trials is to identify the most immunologically-relevant mouse models of IBD and pharmacologic strategies that most closely mimic the clinical situation. This review presents a critical evaluation of the different mouse models and pharmacological approaches that may be used in intervention studies as well as discuss emerging issues related to study design and data interpretation of preclinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.